Polymerization of the amyloid L-peptide (AL) has been identified as a major feature of the pathogenesis of Alzheimer's disease (AD). Inhibition of the formation of these toxic polymers of AL has thus emerged as an approach to developing therapeutics for AD. Techniques for studying AL polymerization include the use of fibril nucleation and extension assays in a variety of formats. Detection of polymeric forms of AL has been achieved using turbidity, dye binding, light scattering and toxicity among other methods. Direct and indirect methods have been described for the measurement of binding affinities for AL fibrils. Imaging techniques include electron microscopy, X-ray diffraction and atomic force microscopy. These techniques have been used to characterize different classes of compounds that inhibit the formation of AL polymers. These compounds include dyes such as Congo Red, the antibiotic rifampicin, the anthracycline 4P-iodo-4P-deoxydoxorubicin, and a large variety of AL-derived peptides and modified peptides, among other reported inhibitors. ß
Introduction
Polymerization of the amyloid L-peptide (AL) has been identi¢ed as a major feature of the pathogenesis of Alzheimer's disease (AD) [1, 2] . Consistently, increased risk for disease is associated with conditions that support increased formation of polymerized AL [3, 4] . Monomeric AL is produced during normal metabolism and appears to have no deleterious e¡ects on neurons [5, 6] and the amyloid precursor protein (APP) has been shown to have memory enhancing properties in mice [7, 8] . As AL assembles into oligomeric forms and eventually into the amyloid ¢brils that are deposited in the neuritic plaques characteristic of AD, it acquires high neuronal toxicity [9^16] . Inhibition of the formation of these toxic polymers of AL has thus emerged as an approach to developing therapeutics for AD [17, 18] .
De¢nitive treatment or cure of AD does not currently exist. The available therapies, cholinesterase inhibitors, modestly delay the progression of disease and near-term goals for therapy may have to be lim-ited to continued improvements in slowing disease rather than eradicating it [19] . Additional modes of therapeutic intervention are under active or proposed clinical evaluation. Inhibition of the formation of toxic forms of AL is one of these approaches that is still waiting to be tested in the clinic.
Lansbury has extensively discussed the amyloid hypothesis of AD, evidence for and against it, and four approaches to therapeutic intervention based on current knowledge of AD pathogenesis and AL biochemistry [18] : (1) inhibit expression of APP; (2) inhibit production of AL peptide(s); (3) inhibit amyloid ¢bril formation; (4) inhibit the toxicity of AL ¢brils. Inhibition of the formation of toxic polymeric AL targets what is believed to be a singularly pathological event, and is therefore viewed as a preferred therapeutic strategy [18] . This article reviews reported inhibitors of AL polymerization and assays used to characterize them.
AL L peptide
Historically, working with full-length AL of 39^43 residues in length was di¤cult because of variations in the properties of di¡erent preparations of the peptide. Characterization of preparations by their neurotoxicity used to be the norm until it became apparent that properly prepared AL should be non-toxic to begin with. At present, numerous laboratories both commercial and academic have demonstrated the ability to synthesize, purify and store AL peptides of consistent quality. Most AD researchers are using the 40 and 42 residue lengths of AL as the major forms to work with. The shorter form is the primary length in circulation and is also easier to synthesize and purify. The longer form is believed to be more signi¢cant in pathogenesis but is harder to prepare and use in some assays. With respect to polymerization inhibitors, most inhibitors of one peptide are expected to act on the other with the exception of something like an AL 1À42 C-terminal speci¢c antibody. Testing a compound of particular interest on both peptides is preferred, however. As for using truncated AL fragments, of which AL 1À28 and AL 25À35 have been popular in the past, it seems illadvised to use them because of their di¡erences from the documented major in vivo pathological forms.
Assays
There are two general forms of assay for AL polymerization, ¢bril nucleation and ¢bril extension [202 2] . Fibril binding can also be measured. Di¡erent laboratories cited in the text have implemented these types of assays in a variety of ways. Fibril nucleation assays measure the time required for a solution of initially monomeric AL to form nuclei to initiate ¢-brillogenesis and the extent of ¢bril formation that ensues. Fibril formation can be measured by apparent absorbance in an ultraviolet/visible spectrometer ( [20] and references therein) or by right-angle light scattering in a £uorimeter, by dye binding [23^26] , and by measurement of the toxicity of the ¢bril solution. Fibril extension assays are similar to nucleation except that the solution of AL monomer is seeded at the beginning of the assay with a small amount of preformed AL ¢bril. This added ¢bril seeds the formation of additional ¢brils immediately without the delay or lag observed in the nucleation assay. Fibril or plaque binding assays have been performed in several di¡erent formats. Typically, a known ligand is radiolabeled and a competition assay is performed, monitoring displacement of the label by a test compound [27, 28] . An alternative approach is to measure the binding of labeled AL to solid-phase test compound [29] . Light scattering has also been used to monitor AL ¢brillogenesis ( [30, 31] and references therein). For general use, a nucleation assay combined with a cell toxicity assay may represent the best approach to screening compounds. While unsuited to high throughput assays, electron microscopy (EM) has been widely used to document the absence or presence of ¢brillar AL. X-ray di¡rac-tion has also been used to characterize amyloid ¢brils [32, 33] . Atomic force microscopy has been demonstrated to be extraordinarily e¡ective for imaging amyloid ¢brils and preliminary data indicate that this technique is useful in studying the mechanism of ¢bril assembly [34^37].
Congo Red (CR) and analogs
CR is a histological azo dye commonly used to identify amyloid plaque because of the characteristic birefringence of ¢brils stained with it (CR, 1). CR is also reported to inhibit the toxicity of AL 1À40 by blocking ¢bril formation and by binding to preformed ¢brils and reducing their toxicity [38] . For AL 1À42 , CR blocked the toxicity of ¢brils but did not prevent their formation [38] . In a more recent study, CR was reported to increase monomer/oligomer ratios in cell culture by stabilizing AL monomer to aggregation rather than by promoting an increase in AL formation or inhibiting AL degradation [39] . An ED 50 of 3.4 WM CR was reported e¡ective to inhibit the toxicity of V10 nM AL at a V300 molar excess of CR. The dissociation constant of CR from AL 1À40 ¢brils in a competition assay has been reported to be 0.5 WM [27] , comparable to its potency in cell culture. It is noteworthy that a patent has been issued for the use of CR to treat various forms of amyloid disease [40] .
Analogs of CR have been reported resulting from e¡orts to make potential diagnostic agents for AD based on imaging amyloid plaque. Chrysamine G (CG), a CR analog in which the sulfonate groups are replaced by carboxylates, was prepared as a more lipophilic compound [41] with a greater potential brain availability. The binding a¤nity of CG to AL 10À43 was determined to be 0.4 WM using a competition assay. CG was also reported to inhibit the polymerization-associated toxicity of the small 25^35 fragment of AL at a concentration of s 0.2 WM on PC12 cells [42] . Other analogs of CR and CG prepared as potential single-photon emission computerized tomography imaging agents have been described [27] . These compounds contain bipyridyl moieties to chelate technetium and were characterized based on their ability to bind to AL 1À40 ¢brils. The free bipyridyl analogs and technetium^tetrakis(t-butylisocyanide) complexes had dissociation constants of 0.160 .76 WM. 
Rifampicin and other rifamycins
The rifamycins are a group of naphthohydroquinone-containing antibiotics. Observations that leprosy patients had a reduced risk of AD ( [43] and references therein, but see also [44] ) resulted in the identi¢cation of the anti-leprosy drug rifampicin (2) as an AL polymerization inhibitor [45, 46] . Fibril formation in vitro and toxicity to PC12 cells was inhibited by a V5-fold molar excess of 2 and several analogs and, in a subsequent study, additional analogs of 2 were studied to explore the SAR for inhibition [47] . The standard thio£avine T (Th-T) dye binding assay was used to observe dose-dependent inhibition of aggregation and toxicity and EM was used to monitor the reduction of ¢bril formation in inhibited mixtures. The SAR pro¢le of the rifamycins suggests that inhibition results from the inclusion of the naphthohydroquinone/naphthoquinone moiety. While this group has radical scavenging properties which are associated with protective e¡ects in AD patients, the pro¢le of these inhibitors is similar to others that seem most likely to act by direct binding to AL.
IDOX (3) is an analog of the anthracycline anticancer agent doxorubicin. In a clinical trial for the treatment of amyloid light-chain disease, unexpected anti-amyloidogenic e¡ects suggested the examination of the in vitro amyloid binding properties of IDOX [48] . IDOX was found to bind with high a¤nity to ¢ve di¡erent types of natural amyloid ¢brils including that of AL. Insulin ¢bril binding competition studies indicated structurally distinct binding sites for IDOX and CR. In the Syrian hamster prion disease model, IDOX-pretreated scrapie-infected brain homogenate was slower to induce disease and resulted in increased survival times [49] . A challenge in the therapeutic application of IDOX is its toxicity and analogs with improved safety are probably re-quired for clinical development as anti-amyloid agents.
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Acridinones
A screening program at Parke-Davis identi¢ed a class of 9-acridinone derivatives with anti-aggregation activity [50] . These compounds were previously discovered as anti-bacterial and anti-tumor agents and apparently were available from the company's compound inventory. Inhibition of L-amyloid aggregation was performed using a 0.2 Wm ¢ltration-based assay in which AL 1À40 was initially dissolved in hexa£uoroisopropanol and diluted to a ¢nal concentration of 40 WM in sodium phosphate bu¡er. In this assay, 1-(3-dimethylaminopropyl-1-amino)-4-nitro-7-methylmercapto-9-acridinone (4) was reported to have an IC 50 of 7.1 WM. An assay for inhibition of AL deposition onto human brain tissue is also described brie£y in this patent. 
Benzofurans
A SmithKline Beecham group has reported a series of benzofuran derivatives that inhibit ¢bril formation [51] . A representative potent inhibitor SKF-74652, 5, was characterized in several di¡erent assays. In a ¢brillogenesis inhibition assay based on an immunoassay readout and in an AL binding assay based on scintillation proximity, the IC 50 values observed were 28 WM and 11 WM, respectively. The concentration of AL 1À40 in these assays was 11.6 WM, suggesting that the inhibitor may bind even more tightly than suggested by the determined potency in the binding assay.
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Peptides
E¡orts to understand the basis for the ¢brillogenic nature of AL have resulted in a variety of studies in which analogs of AL were synthesized and their ability to form amyloid ¢brils evaluated. Among these studies was a report that showed that substitution of the phenylalanyl^phenylalanyl dipeptide at positions 19^20 in the AL sequence could produce peptides that had increased solubilities [52] . In combination with native-sequence AL, the Phe-substituted analogs inhibited formation of amyloid ¢brils [52] . This result showed how a large AL peptide could have decreased amyloidogenicity by altering this hydrophobic core region. Such peptides are of limited interest for therapeutic development because of their large size and presumed limited bioavailability and biostability. A related approach is to take advantage of the importance of the Phe^Phe sequence and adapt it to the design of inhibitors. Several groups have pursued this strategy.
Early studies with organic-modi¢ed peptides established the feasibility of using peptides derived from fragments of AL as inhibitors [53, 54] . Combining an organic modi¢er with an AL binding peptide sequence a¡orded potent and selective inhibitors such as cholyl-LVFFA-OH (6) [55^60]. An equimolar concentration of this compound in the range of 0.2V50 WM monomeric AL 1À40 blocked ¢bril formation inde¢nitely and at lower concentrations, it was able to signi¢cantly delay ¢bril formation and extension assays were potently inhibited in a similar manner [56] . Testing of assay mixtures in cell culture showed that the delay in polymerization corresponded to a delay in the formation of toxic forms of AL. Extension of this work demonstrated that organic-modi¢ed all-D [59^61] and sequence-modi-¢ed AL-derived all-D peptides [61] are potent inhibitors of AL polymerization and toxicity. LVFFAbased compounds with increased potency have been obtained by substitution of the alanyl residue with a larger hydrophobic residue such as leucine. These substitutions were made within inverso (all-D) or retroinverso (all-D reverse) sequences [61] .
Further study of these peptidic inhibitors demonstrated that in addition to ¢brillogenesis and toxicity inhibitory activities, they also inhibited the AL-induced neurocytopathic activation of monocytes, thus demonstrating inhibition of indirect AL toxicity [62] . The mechanism of inhibition of monocyte activation may involve interference with internalization rather than binding [63] .
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In a similar study, decapeptides from the AL sequence were synthesized and assayed for AL binding to identify residues important for AL self-recognition [29] . As in other similar studies, the approximate positions of 10V20 were identi¢ed as important and further work identi¢ed the peptide acetyl-QKLVFF-NH 2 as an AL polymerization inhibitor (7) . EM was used to observe a lack of ¢bril formation by 100 WM AL 1À40 in the presence of equimolar 7.
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Soto and coworkers have described a related approach based on the AL 17À21 (LVFFA) region. This strategy was based on the substitution of proline into peptides based on AL to reduce the ability of the peptides to adopt L-conformation [64^66]. Using £uorescence quenching techniques, a dissociation constant of 76 nM for the 11 residue peptide RDLPFFPVPID, an analog of QKLVFFAEDVG (AL 15À25 ), was determined for binding to AL 1À40 [61] . Using high concentrations of AL (V200 WM) and inhibitors in high relative molar excess, ¢bril formation was inhibited and ¢bril dissociation was promoted. The all-D peptide was also described as comparably inhibitory. In a subsequent study, a ¢ve residue peptide, LPFFD, was shown to be a potent inhibitor of AL 1À42 ¢brillogenesis and cellular toxicity. When coinjected into rat brain with AL 1À42 , a 20-fold molar excess of this inhibitor reduced cerebral amyloid deposition [65] .
In an approach to inhibitor design similar to those above, an oligolysine sequence was appended to AL 15À25 to introduce a disrupting element [67] . The resulting inhibitor reduced amyloid formation as measured using a Th-T assay and EM, and corresponding inhibition of toxicity was observed in cell culture. Laser light scattering techniques were used to determine that similar compounds inhibiting AL toxicity did not prevent aggregation. Instead, the aggregates detected formed with di¡erent kinetics and had an altered structure [31] .
Other inhibitors
A variety of additional reports describe compounds that have been characterized by at least one method to bind to AL or to inhibit its ¢brillogenesis. For instance, polyanionic compounds have been prepared as amyloid inhibitors [68^70]. In particular, 1,3-propanediol-disulfate is a potent inhibitor in a mouse model of serum amyloid A amyloidosis. A subsequent study showed apparent disassembly of preformed AL 1À40 ¢brils when treated with a 10-fold molar excess of this compound. These compounds are very polar and limited central nervous system availability may limit their practical application to the treatment of peripheral amyloidoses.
Increased risk for development of AD is associated with the presence of the O4 variant of apolipoprotein E (ApoE) [71, 72] . One proposed mechanism for the increased risk associated with the O4 allele is that ApoE O4 appears to be a less e¡ective inhibitor of ¢bril nucleation than the O2 and O3 variants [73^75].
Antibodies speci¢c for AL have also been described to inhibit ¢bril formation and to promote ¢bril disaggregation [76] . Systemic dosing of an antibody may be problematic with respect to achieving access to and e¤cacy in the central nervous system. The recent report of success in vaccinating PDAPP transgenic mice with AL 1À42 emulsi¢ed with complete Freund's adjuvant to elicit endogenous antibodies may o¡er a more practical though unexpected alternative [77] .
L-Cyclodextrin (cycloheptaamylose) has been reported to inhibit the cellular toxicity of AL [78] . Mass spectrometric analysis was used to infer noncovalent complexation of cyclodextrin with AL via interaction with hydrophobic aromatic residues on the peptide. Moderate inhibition of toxicity to PC12 cells was reported. Direct evidence for an e¡ect on the state of aggregation of the AL (such as by EM) and its correlation with cell viability was not presented however.
Th-T is a £uorescent histological dye now well established as a reporter molecule for amyloid polymerization assays [23^25]. It is a general amyloid dye, like CR, and therefore does not represent a speci¢c binder of AL. Unlike CR, Th-T is not reported to be an inhibitor of AL polymerization but its a¤nity for AL may be adaptable to the development of inhibitors. The selectivity of Th-T binding for ¢brils suggests that the resulting compounds might only interfere with ¢bril extension rather than inhibit initiation of ¢brillogenesis.
Quarternary ammonium compounds were identi¢ed from screening a 4300 component library for inhibition of AL polymerization. The most potent inhibitor reported was N-hexadecyl-N-methylpiperidinium bromide [26] with an IC 50 in the WM range based on nucleation assay data.
Nuclear magnetic resonance techniques have been used to characterize the interaction of the heterocyclic compounds nicotine [79] and melatonin [80] with AL. Inhibition of polymerization was not correlated with cellular toxicity in these reports. Nicotine^AL interactions were interpreted to suggest that a nonpathogenic conformation of AL was stabilized. This concept has been demonstrated in the use of a smallmolecule ligand of TTR tetramer to inhibit ¢brillo-genic changes in conformation [81] .
Overview
A variety of techniques have been developed to study the polymerization of AL and they are being applied to the development and characterization of several classes of compounds that are potent inhibitors of AL polymerization (for references in addition to those cited above, see [82] ). Further reports of the use of these compounds in increasingly robust animal models of AD should be anticipated. An additional area in which these various techniques and compounds should prove to be useful is in the characterization of the mechanism of AL polymerization. Progress in this regard will facilitate further development of polymerization inhibitors and eventual human clinical testing. Increasing understanding in the mechanisms by which AL is produced [83, 84] and how it interacts with other proteins in vivo [85] will also support more re¢ned approaches to developing improved therapeutics for AD. Observations that AL deposits in vivo are porous and dynamical undergo aggregation and disaggregation [86] in combination with clinical observations that other amyloid diseases can be treated [48, 87, 88] suggests that practical therapies can be developed.
